US 11,812,740

Application 16/615,085 · Granted Nov 14, 2023

Method for genetically modifying a vascularised tissue

Estimated expiration

November 15, 2040

13y 363d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTEP2018063581: Resource not found (404)
Earliest effective filing
May 23, 2018
+ 20 years
May 23, 2038
PTA +907d
Nov 15, 2040
No TD
—
Final
Nov 15, 2040

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
November 19, 2019
Earliest effective filing
May 23, 2018
Issue date
November 14, 2023
PTA
+907 days
Base expiry (before PTA)
May 23, 2038

May 23, 2018 + 20 years = May 23, 2038 + 907 PTA days = November 15, 2040

  • National stage entry of application PCTEP2018063581, filed May 23, 2018

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 16/615,085 · US 11,812,740

PatentReply compiles the prosecution history behind US 11,812,740: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US11812740

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.